CagriSema for Obesity
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug CagriSema for obesity?
Research shows that semaglutide, a component of CagriSema, is effective in causing significant and sustained weight loss in people with obesity. Additionally, cagrilintide, when combined with semaglutide, has shown promising results in further enhancing weight loss, making this combination a potentially effective treatment for obesity.12345
Is CagriSema safe for humans?
How is the drug CagriSema unique for treating obesity?
CagriSema combines two drugs, semaglutide and cagrilintide, which work together to reduce appetite and promote weight loss. This combination targets different pathways in the brain to enhance the feeling of fullness, making it a novel approach compared to other treatments that typically focus on a single mechanism.2351011
What is the purpose of this trial?
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.
Research Team
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Eligibility Criteria
This trial is for individuals with excess body weight, commonly referred to as obesity. Participants will be randomly assigned to receive either the experimental medication CagriSema or a placebo (dummy medicine) and will participate in the study for approximately 1½ years.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive once-weekly subcutaneous injections of CagriSema or placebo for weight loss, with dose escalation over 8-12 weeks and maintenance for up to 60-68 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CagriSema
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen